Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Abdulla A. Damluji, MD, PhD Profile picture
@DrDamluji
Nov 5, 2021 • 26 tweets • 17 min read • Read on X
Scrolly
SURTAVI

No differences in death ,stroke, MI, or HF between TAVR and Surgery during longer follow-up

#TCT2021
Hemodynamics

Total AR and PVL

KCCQ no difference after 1 year

NYHA class at one year 1
Summary for SURTAVI

Self expanding valve

#TCT2021
Excellent!
5 year data for 4,000 patients is now out (intermediate risk).

@djc795
Economic outcomes of PARTNER #3

@djc795

Cost effectiveness study along side of PARTNER 3 trial

funded by Edwards
Costing: definitions

US population only

Medicare data link
Results Baseline

TAVR vs SAVR PARTNER 3 Economic Study
Index Hospital Costs

Follow-up Cost
Overall no cost difference

QALY difference (borderline?!)

#TCT2021
All costs and effects discounting

TAVR is cost effective
Subgroups (pre-specified)

Sensitivity analyses

#TCT2021
Sensitivity Analyses
Summary!

84% CI that we will improve outcomes and at the same time achieve cost effectiveness.

10 year outcomes will affect cost effectiveness - to come...

Outstanding presentation @djc795 @DrMauricioCohen

#TCT2021
"When mortality rate is the same between SAVR and TAVR: patient preference is what matter next."

"No one wants a sternotomy."

@djc795

#TCT2021
CHOICE CLOSURE

Vascular Closure for TAVR but this also applies to shock space also (Safety Bundle)

#TCT2021

@Radial_ICG @behnam_tehrani @agtruesdell @ShashankSinhaMD @JACCJournals
Available Evidence

Aim Choice Closure

Randomization: pure plug based vs primary suture based

#TCT2021
Inclusion and Exclusion

Primary Endpoint
Secondary Endpoints

Study Methods

Angioseal was used...

3 Locations in Germany

#TCT2021
Study Flow

258 MANTA vs 258 ProGlide

#TCT2021
Baseline Results

Vessel Characteristics

Procedural Details

Low ultrasound use?! @Radial_ICG

#TCT2021
Manta had higher complications!!

Important data!

#TCT2021
Subgroup analysis

Hospital Outcomes

30-Day Outcomes

#TCT2021
Limitation
Conclusion

Excellent trial @Mo_A_W

Applies to shock too

***Editorializing: Losing the wire access with MANTA is a big problem.

#SafetyBundle

#TCT2021
Comparison of a Pure Plug-Based versus a Primary Suture-Based Vascular Closure Device Strategy for Transfemoral Transcatheter Aortic Valve Replacement: The CHOICE-CLOSURE Randomized Clinical Trial

@CircAHA

ahajournals.org/doi/abs/10.116…

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Abdulla A. Damluji, MD, PhD

Abdulla A. Damluji, MD, PhD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @DrDamluji

Abdulla A. Damluji, MD, PhD Profile picture
Mar 23
Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary InterventionA Systematic Review and Patient-Level Meta-Analysis: @JAMACardio

🥸 Good morning: more on SAPT monotherapy vs DAPT

😱Summary

👇👇👇 Image
1.🥸 Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is standard post-PCI to minimize ischemic events, but it increases bleeding risk. Emerging studies prompt a reassessment.

😱 Mainly, in high risk groups: older adults.
2. 🥸 Short DAPT durations followed by P2Y12 inhibitor monotherapy have shown promising reductions in bleeding but raised concerns re ischemic risks in high-risk patients.
Read 13 tweets
Abdulla A. Damluji, MD, PhD Profile picture
Mar 14
Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main Disease With or Without Diabetes: Findings From a Pooled Analysis of 4 Randomized Clinical Trials: @CircAHA

🥸wow: more on left main+diabetes: PCI vs CABG!

😱 Summary

👇👇👇 Image
1/ 🥸 Left main coronary artery disease and diabetes are associated with substantial cardiovascular morbidity and mortality.
2/ 🥸 Yet, long-term outcomes for patients with left main disease and diabetes undergoing PCI compared with CABG remain unclear.
Read 22 tweets
Abdulla A. Damluji, MD, PhD Profile picture
Dec 3, 2023
Critical Care Management of Patients After Cardiac Arrest: A Scientific Statement From the American Heart Association and Neurocritical Care Society: @CircAHA

🥸Great work: @AHA_Research @AHA_AcuteCVCare

😱Let's summarize: Happy Sunday :)

👇👇👇 Image
1/🥸 Cardiac Arrest Prevalence: Over 600,000 individuals in the US experience cardiac arrest annually.

😱This is a significant public health problem.
2/ 🥸 Worldwide Incidence: Globally, cardiac arrest occurs in 30 to 97 individuals per 100,000 population.
Read 21 tweets
Abdulla A. Damluji, MD, PhD Profile picture
Nov 12, 2023
Great #AHA23 so far: @AHA_Research

🥸8 Trials: 8 take aways below

Read the read👇👇

1/ATRESIA:

Patients with subclinical atrial fibrillation can benefit from apixaban to reduce the risk of stroke and systemic thromboembolism. Image
2/CARDIA-SSBP:

🥸The decline in SBP with a low-sodium diet was independent of hypertension status and anti-hypertensive medication use, consistent across subgroups, and did not result in excess adverse Image
3/ CRHCP:

🥸Intensive BP lowering (target BP < 130/80 mm Hg) significantly reduced risk of all-cause dementia among patients with hypertension, supporting the use of intensive hypertension treatment to reduce the burden of dementia.

😱 @cardskrish Image
Read 11 tweets
Abdulla A. Damluji, MD, PhD Profile picture
Nov 11, 2023
Semaglutide and Cardiovascular Outcomes
in Obesity without Diabetes: @NEJM

The select trial: #AHA23

🥸Wow! @AHA_Research

😱Now on the stage in main event

😱Let's get the highlights

👇👇👇 Image
1.🥸 GLP-1 receptor agonists are known for cardiovascular benefits in type 2 diabetes.
2.🥸 The SELECT trial tested semaglutide, a potent member of GLP-1 class of drugs, for cardiovascular risk in overweight individuals without diabetes history.
Read 19 tweets
Abdulla A. Damluji, MD, PhD Profile picture
Oct 22, 2023
Frailty-Guided Management of Cardiovascular Disease— From Clinical Trials to Clinical Practice: @JAMACardio

🥸More on this in @JACCJournals soon...

Discussion below -

👇👇 Image
🥸1. Frailty is a reduced physiological reserve and increased vulnerability to stressors.

😱 Important for CVD Management and Interventional Cardiology Procedures.
🥸2. There's no single agreed-upon way to measure frailty.

😱 Annoying problem...
Read 28 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

Send Email!

:(